What Kerval Treats: Main Uses and Benefits

Kerval is generally used in situations involving certain symptoms related to systemic imbalance and heightened physiological activity. It is applied across domains where additional symptomatic support is needed for managing chronic conditions.

The main therapeutic areas for this intervention are assisting with the management of elevated blood pressure and supporting patients with kidney disease associated with type 2 diabetes.

Supporting Cardiovascular Health

Kerval is commonly used to help manage essential hypertension—a condition marked by increased physiological stress. This intervention is relevant for easing symptoms related to heightened physiological activity and may assist with maintaining a sense of stability when symptoms are more noticeable.

Assisting with Renal Support in Diabetic Patients

The medicine is considered relevant for patients with type 2 diabetes and high blood pressure where functional stability becomes affected. Applied in clinical settings that involve acute or unstable symptom patterns, it contributes to easing the overall symptom load by supporting the patient during difficult episodes.

---

Quick Fact: Relevant for Heightened Physiological Activity

Kerval may be part of symptomatic management in contexts marked by increased discomfort or tension and assists with managing symptoms that create noticeable functional strain.

Kerval (Valsartan) eligibility is strictly defined by government regulatory documents based on the patient's physiological status and age.

Populations and Conditions for Use

Classification	Population/Condition	Restriction Detail
Contraindicated	Pregnancy (2nd and 3rd trimesters)	Must not be used due to documented fetal toxicity.
Contraindicated	Severe Hepatic Impairment	Prohibited in patients with severe hepatic impairment, biliary cirrhosis, or cholestasis.
Contraindicated	Concomitant Aliskiren Use	Prohibited in patients with diabetes mellitus or GFR <60 mL/min/1.73 m^2 who are also receiving aliskiren.
Not Recommended	Pediatric Patients	Not recommended for children less than 1 year of age and for patients under 18 years being treated for heart failure or post-myocardial infarction.
Conditional Use	Mild to Moderate Hepatic Impairment	Use is restricted; a maximum daily dose limit is specified by regulatory authorities.

---

Age-Related Eligibility Status

Kerval is approved for the treatment of hypertension in adults and in children and adolescents aged 6 to 18 years. Use in the elderly generally requires no initial dosage adjustment. Use is not recommended in the first trimester of pregnancy or while breastfeeding.

---

Eligibility-Context Constraints

Eligibility is limited by specific organ function thresholds; for instance, use is not recommended for pediatric patients with a creatinine clearance <30 mL/min/1.73 m^2 or who are on dialysis.

Interactions with other medicines and products

Kerval (Valsartan) interactions are officially documented in government regulatory sources, highlighting patterns that primarily affect systemic exposure and essential physiological balance, such as renal function and potassium levels.

Official Interaction Patterns

Interacting Substance/Class	Officially Documented Interaction Outcome
Aliskiren	Contraindicated in patients with diabetes mellitus or specific levels of renal impairment (GFR < 60 mL/min/1.73 m^2).
Potassium-sparing diuretics & Supplements	Increased risk of hyperkalemia (elevated serum potassium) and increased serum creatinine.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Increased risk of renal impairment and attenuation of the antihypertensive effect. Risk is greater in the elderly or those with compromised renal function.
Lithium	Potential for reversible increases in serum lithium concentrations and subsequent toxicity.
OATP1B1 Inhibitors (e.g., Rifampicin)	May lead to an increase in Valsartan systemic exposure ( AUC).
Food	Decreases Valsartan systemic exposure ( AUC) by approximately 40% and peak plasma concentration ( Cmax) by about 50%.

Interaction-Related Restrictions

Regulatory information emphasizes constraints related to dual blockade of the Renin-Angiotensin System (RAS). The combination of Valsartan with Aliskiren is specifically prohibited in patients with certain pre-existing conditions. Furthermore, substances that increase potassium, including salt substitutes, must be considered due to the documented risk of significant hyperkalemia. These documented interaction patterns define mandatory constraints for co-administration.

Adrenergic Receptor Blockade and Systemic Modulation

This domain covers Kerval's primary mechanism: acting as an antagonist to block mathbfBeta-1 (beta1) receptors in the heart and mathbfAlpha-1 (alpha1) receptors in peripheral blood vessels. This action dampens the effects of the sympathetic nervous system, which leads to a mathbfslowing~of~the~heart~rate and relaxation of blood vessels that ultimately results in a diminished total load on the circulatory system.

---

Cellular Protection via Antioxidant Activity

Kerval engages a secondary mechanistic domain by exerting antioxidant properties within myocardial tissue. This involves acting as a scavenger of free radicals and inhibiting the mathbfoxidative~stress~cascade. This protective mechanism mathbflimits~cellular~damage and reduces the impact of long-term stress on the heart muscle itself, influencing long-term cellular dynamics.

Administration Route, Form, and Timing

How Kerval is used (active ingredient Valsartan) is dictated by specific protocols concerning administration route, frequency, and population-based adjustments. Kerval is administered orally in the form of tablets or as a specifically compounded oral suspension. The medication may be taken with or without food.

---

Dosing Frequency and Schedules

The required dosing frequency depends on the condition being managed. For the management of high vascular pressure (hypertension), the standard schedule is once daily (QD), typically starting at 80 mg or 160 mg and not exceeding a maximum of 320 mg daily. In contrast, for heart failure and post-myocardial infarction stabilization, the medicine is administered twice daily (BID), starting as low as 20 mg or 40 mg per dose, with dose increases titrated at intervals of at least two weeks. The maximal reduction in blood pressure is generally observed after four weeks of therapy.

---

Population and Procedural Constraints

Special population rules apply to the use of this medication. For pediatric patients (ages 6 to 16) being treated for hypertension, dosing is calculated based on body weight (1.3 mg/kg once daily, up to 40 mg initial total). Furthermore, for adult patients with mild to moderate hepatic impairment that is non-cholestatic, the daily dose must not exceed 80 mg as a procedural constraint. It is also a clinical requirement that the prepared oral suspension and the tablets are not interchangeable on a milligram-per-milligram basis.

Research Evidence / Overview of Studies for Kerval

The research into Kerval (Valsartan) has primarily focused on its use for cardiovascular and renal conditions, including high vascular pressure, heart failure, and support after a heart attack. Findings describe patterns observed in large-scale clinical trials and observational cohorts, which forms the basis for understanding what has been studied in specific patient groups.

---

Evidence for Managing High Vascular Pressure (Hypertension)

Research has utilized large-scale Randomized Controlled Trials (RCTs) to evaluate Kerval in the context of elevated blood pressure, examining changes in measured blood pressure. These studies monitored changes in Systolic and Diastolic Blood Pressure (SBP/DBP). Long-term trials also monitored the occurrence of major cardiovascular events and reported the observed event rates over the observation period.

---

Evidence for Cardiovascular Support Following a Heart Attack

Large-scale Randomized Clinical Trials (RCTs) evaluated Kerval's use in high-risk adults who had experienced an acute myocardial infarction (MI) and showed evidence of left ventricular dysfunction. The primary research focus was to track and document all-cause mortality. Secondary outcomes monitored included cardiovascular mortality and the frequency of hospitalizations for heart failure. Data for patients without significant left ventricular dysfunction is limited within this research structure.

---

Evidence for the Management of Chronic Heart Failure

The core evidence stems from large-scale RCTs that monitored composite outcomes of mortality and morbidity related to chronic heart failure. Research also examined the rates of hospitalization for heart failure over typical follow-up durations. What remains uncertain is that the core evidence was developed before the widespread availability of certain newer combination agents.

---

Research Gaps and Areas of Uncertainty

Research has monitored the urinary albumin excretion rate (albuminuria) in patients with Type 2 Diabetes and hypertension, using this as a marker of kidney function. However, where trials rely on surrogate endpoints (like albuminuria) instead of hard, long-term outcomes (like preventing kidney failure), certainty remains low regarding the ultimate long-term effect. Data for certain high-risk groups, such as children and those with severe kidney impairment, remain limited.

Common questions about Kerval (FAQ)

---

Q: Can I drink alcohol while taking this medicine?

Official regulatory information states that alcohol may increase the effect of Kerval in lowering blood pressure. This combination could increase the chance of experiencing side effects such as dizziness, lightheadedness, or fainting. The drug label describes the potential for increased risk of side effects when Kerval is used with alcohol.

---

Q: Is it safe to take this drug during pregnancy or while breastfeeding?

According to official regulatory warnings, Kerval is not recommended during pregnancy, particularly during the second and third trimesters, due to the documented risk of fetal injury or death. The official label indicates that use while breastfeeding is generally not recommended. These restrictions are prominently noted in the official product information.

---

Q: What should I do if I miss a dose?

Regulatory documents describe the procedure for a missed dose as taking it when remembered, unless it is close to the next scheduled time, at which point the instruction is to skip the missed dose. The label explicitly addresses that taking two doses at once is generally avoided.

---

Q: Will this medicine affect my ability to drive or operate machinery?

Official product information indicates that Kerval may cause side effects such as dizziness or lightheadedness. In rare cases, this may impair a person's ability to perform tasks requiring alertness. The drug label emphasizes the importance of understanding the potential for these effects, which may occur before driving or operating machinery.

---

Q: Is weight gain a common side effect?

In the official regulatory safety data, weight gain is not specifically listed among the most commonly reported side effects. The adverse reaction listings detail more frequent events such as dizziness, hypotension (low blood pressure), and headache, based on clinical trial data.

---

Q: Can this drug cause mood changes or insomnia?

Official regulatory sources list insomnia (trouble sleeping) as an uncommon possible side effect, based on reports from clinical trials or post-marketing experience. Mood changes are not prominently listed among the common or uncommon reported adverse events.

---

Q: Is this medicine a controlled substance?

Kerval is a prescription-only medication whose active ingredient is Valsartan. According to official regulatory listings in the United States, the medicine is not classified as a federally controlled substance.

Official Storage and Disposal Requirements

Item	Official Regulatory Requirement
Storage Temperature	Tablets: Controlled room temperature (20 C to 25 C / 68 F to 77 F). Suspension: Store below 30 C or refrigerated (2 C to 8 C).
Handling Constraints	Keep the medicine from freezing and store away from excess heat, moisture, and direct light. Tablets must be kept in the original, tightly closed container.
Stability Period	The compounded oral suspension remains stable for 30 days at room temperature or 75 days when stored under refrigeration; outdated product must be discarded.
Child Protection	Must be kept out of the sight and reach of children and pets; always ensure safety caps are locked and the medicine is stored securely.
Disposal Instructions	The preferred method for discarding unused or expired Kerval is a drug take-back program. As an alternative, if no program is available and the medicine is not on the official flush list, mix it with an undesirable substance (e.g., dirt) and place it in a sealed container before disposal in the household trash. Do not flush down the toilet.